Gallant Therapeutics is an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets. They are focused on developing allogeneic stem cell therapies from their stem cell platform and providing non-invasive stem cell banking during the spay or neuter process. Their first product targets Feline Chronic Gingivostomatitis (FCGS) and they are also developing therapies for osteoarthritis, atopic dermatitis, chronic kidney disease, and other chronic diseases in dogs and cats.

Gallant Therapeutics

Gallant Therapeutics is a clinical-stage animal health biotechnology company setting a new standard in animal health by harnessing the power of stem cell therapy to treat the root cause of diseases in dogs and cats. Our pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies has the potential to treat a broad range of diseases, including canine and feline osteoarthritis (OA), feline chronic kidney disease (CKD), and others. The first product based on our uterine-derived platform for feline chronic gingivostomatitis (FCGS), is on track for conditional approval by the FDA in 2025. United by a love of and commitment to animals, Gallant’s team includes industry pioneers in veterinary regenerative medicine with deep experience in cell therapy product development, manufacturing and commercialization.

We are advancing a pipeline of off-the-shelf therapies to bring the benefits of stem cell therapy to pets and their parents.

Gallant is proud to be at the forefront of this science, fast-tracking innovative products in regenerative medicine to revolutionize the well-being of animals – making every (pet) year count. https://bit.ly/47R32x0 #veterinarymedicine #innovation

We're working hard to bring the life-changing benefits of stem cell therapies to pets. 

In this spirit, we celebrate #PetAwarenessMonth and our gratitude for our pets and the many ways they enrich our lives. #gratitude #pets #animalhealth #pethealth

Feline chronic gingivostomatitis (FCGS) is a debilitating dental disease impacting about 2 million domestic cats.

At Gallant, we are develeping a stem cell therapy targeting the root cause of this disease. In our pilot clinical trials, this investigational therapy has demonstrated positive results, helping to improve painful oral lesions, increasing owner's assessment of cat's quality of life, giving owners hope, and helping save lives of cats with refractory disease that have no other option. 

👉Follow us on Linkedin to stay up-to-date on our #clinicaltrials. FMI: https://bit.ly/3skFfXb #animalhealth #research #stemcells #veterinarymedicine

The possibilities that #regenerativemedicine opens up for improving the well-being and longevity of people and our cherished pets are a source of great excitement. At Gallant Therapeutics, we are dedicated to advancing #veterinarymedicine in pursuit of these goals.

Listen in as our CEO, Linda Black, DVM, PhD., joins the latest episode of the Veterinary Innovation Podcast to discuss her journey & how stem cell therapies could transform veterinary care by treating the root causes of diseases like osteoarthritis and feline chronic gingivostomatitis. #innovation #podcast #biotechnology

We are setting a new standard in animal health, harnessing the power of stem cell therapy to treat the root cause of diseases in pets to help them live healthier, longer lives.  

Learn more about the potential of our stem cell therapies: https://bit.ly/3tYNmc4
#animalhealth #stemcells #veterinarymedicine #regenerativemedicine #innovation

It's National Cat Day. We're celebrating our feline friends today and the companionship, joy, and love they bring to our lives. 

Our affection for cats is unique; we're pioneering stem cell treatments for feline diseases with limited or no treatment options so that they can live longer, healthier lives. 

Thanks to cat-parent Nopmanee Taechangam DVM, M.Sc., Ph.D. for sharing this adorable photo with us! #animalhealth #veterinarymedicine #stemcells #innovation

Metric
Company Name	Gallant Therapeutics
Symbol
MSH ID	COM:GALLANTTHERAPEUTICS
Market	PRIVATE
Sector	Animal Health
Industry	Biotechnology
Country	US
Stage
Employee Count	41
Website	gallanttherapeutics.com
LinkedIn	gallanttherapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	7.31
28-Day Growth Score	12.53
90-Day Growth Score	9
365-Day Growth Score	25.79

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:GALLANTTHERAPEUTICS

Gallant Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue